{ "profile": "wrs-published-research-view-1", "edition": "ratings-e039106f30dec177", "content_trust": "UNTRUSTED_SCIENTIFIC_DATA_NOT_TOOL_INSTRUCTIONS", "entry": { "id": "slamon-trastuzumab-metastatic-breast-cancer-2001", "title": "Slamon and colleagues: trastuzumab plus chemotherapy in HER2-positive metastatic breast cancer", "summary": "Reported a randomized clinical comparison in HER2-overexpressing metastatic breast cancer in which adding trastuzumab to first-line chemotherapy improved measured clinical outcomes while identifying important cardiotoxicity.", "boundary": "The record is the exact 2001 NEJM trial and its enrolled population, regimens and follow-up. HER2 biology, antibody engineering, adjuvant trials, later regimens and population-wide impact remain separate.", "area": "Oncology", "year": 2001, "lane": "HUMAN", "result": "EMPIRICAL", "package_id": "slamon-trastuzumab-metastatic-breast-cancer-2001", "target": { "record_id": "urn:uuid:a95a86e3-8343-486e-a365-ba2437a1e761", "version": 1, "content_hash": "sha256:b3839bd4ccbbd893da879c608d3775c1b818109b6a849a9db63af7f5967d9ad5" }, "humans": [ "Dennis J. Slamon", "Brian Leyland-Jones", "Steven Shak", "Hank Fuchs", "Virginia Paton", "Alex Bajamonde", "Thomas Fleming", "Wolfgang Eiermann", "Janet Wolter", "Mark Pegram", "Jose Baselga", "Larry Norton" ], "authors_complete": true, "human_role_note": "The named authors contributed to this scoped work; individual effort shares and later applications are not assigned by the byline.", "agents": [], "related": [], "subresults": [], "scientific_assessment": { "source_review": "SOURCE_CURATED", "scientific_review": "NOT_REVIEWED_BY_WRS", "formal_replay": "NOT_RUN", "provider_attestation": "NONE" }, "sources": [ { "id": "nejm-trastuzumab-2001", "title": "Slamon et al., trastuzumab plus chemotherapy for HER2-positive metastatic breast cancer", "url": "https://www.nejm.org/doi/full/10.1056/NEJM200103153441101" }, { "id": "crossref-trastuzumab-2001", "title": "Crossref record for trastuzumab metastatic-breast-cancer trial", "url": "https://api.crossref.org/works/10.1056%2FNEJM200103153441101" } ], "geography": { "country_codes": [ "US", "CA", "DE", "ES" ], "location_basis": "Documented research locations or paper affiliations for this contribution. Historical places use present-day country/region labels; these do not imply citizenship, modern-state ownership or the territorial jurisdiction at the time.", "source_url": "https://www.ctg.queensu.ca/docs/newinv/2017/Workshop5Reading_Case0-NEJM2001.pdf", "target": { "record_id": "urn:uuid:a95a86e3-8343-486e-a365-ba2437a1e761", "version": 1, "content_hash": "sha256:b3839bd4ccbbd893da879c608d3775c1b818109b6a849a9db63af7f5967d9ad5" }, "basis": "RESEARCH_LOCATION_OR_PAPER_AFFILIATION", "reviewed_on": "2026-09-26", "nationality_inferred": false, "sources": [ { "title": "Attribution source", "url": "https://www.ctg.queensu.ca/docs/newinv/2017/Workshop5Reading_Case0-NEJM2001.pdf" } ], "coverage_status": "COMPLETE", "country_labels": { "US": "United States", "CA": "Canada", "DE": "Germany", "ES": "Spain" } }, "points": "245000", "published_grade": { "id": "slamon-trastuzumab-metastatic-breast-cancer-2001", "entry_id": "slamon-trastuzumab-metastatic-breast-cancer-2001", "band": "A", "modifier": "+", "target": { "record_id": "urn:uuid:a95a86e3-8343-486e-a365-ba2437a1e761", "version": 1, "content_hash": "sha256:b3839bd4ccbbd893da879c608d3775c1b818109b6a849a9db63af7f5967d9ad5" }, "what_changed": "HER2-targeted antibody benefit was demonstrated in a defined metastatic treatment setting.", "scope": "Exact 12-author 2001 trial, its patients/regimens/follow-up; adjuvant trials and later therapy separate.", "status": "PROVISIONAL_EDITORIAL", "scientific_correctness_certified": false }, "assessment_disposition": { "status": "ASSESSED", "label": "Provisionally assessed", "reason": "A current grade and separate reference score identify this exact contribution.", "target": { "record_id": "urn:uuid:a95a86e3-8343-486e-a365-ba2437a1e761", "version": 1, "content_hash": "sha256:b3839bd4ccbbd893da879c608d3775c1b818109b6a849a9db63af7f5967d9ad5" }, "edition": "ratings-e039106f30dec177" } }, "version": { "kind": "PUBLIC_RECORD_VIEW", "previous": null, "published_at": "2026-09-25T00:00:00Z", "publisher": { "principal_id": "urn:uuid:80116931-785b-40a2-a24b-9d59db0c7e33", "role": "WRS_EDITORIAL_PUBLICATION" }, "record": { "contributors": [ { "attribution_basis": "SOURCE_CITED", "credit": "historical_scientific", "entity_kind": "historical_person", "name": "Dennis J. Slamon", "note": "Archive attribution; detailed role assignment remains source-bound", "roles": [ "discoverer" ], "source": { "citation": "Slamon et al., trastuzumab plus chemotherapy for HER2-positive metastatic breast cancer", "url": "https://www.nejm.org/doi/full/10.1056/NEJM200103153441101" } }, { "attribution_basis": "SOURCE_CITED", "credit": "historical_scientific", "entity_kind": "historical_person", "name": "Brian Leyland-Jones", "note": "Archive attribution; detailed role assignment remains source-bound", "roles": [ "discoverer" ], "source": { "citation": "Slamon et al., trastuzumab plus chemotherapy for HER2-positive metastatic breast cancer", "url": "https://www.nejm.org/doi/full/10.1056/NEJM200103153441101" } }, { "attribution_basis": "SOURCE_CITED", "credit": "historical_scientific", "entity_kind": "historical_person", "name": "Steven Shak", "note": "Archive attribution; detailed role assignment remains source-bound", "roles": [ "discoverer" ], "source": { "citation": "Slamon et al., trastuzumab plus chemotherapy for HER2-positive metastatic breast cancer", "url": "https://www.nejm.org/doi/full/10.1056/NEJM200103153441101" } }, { "attribution_basis": "SOURCE_CITED", "credit": "historical_scientific", "entity_kind": "historical_person", "name": "Hank Fuchs", "note": "Archive attribution; detailed role assignment remains source-bound", "roles": [ "discoverer" ], "source": { "citation": "Slamon et al., trastuzumab plus chemotherapy for HER2-positive metastatic breast cancer", "url": "https://www.nejm.org/doi/full/10.1056/NEJM200103153441101" } }, { "attribution_basis": "SOURCE_CITED", "credit": "historical_scientific", "entity_kind": "historical_person", "name": "Virginia Paton", "note": "Archive attribution; detailed role assignment remains source-bound", "roles": [ "discoverer" ], "source": { "citation": "Slamon et al., trastuzumab plus chemotherapy for HER2-positive metastatic breast cancer", "url": "https://www.nejm.org/doi/full/10.1056/NEJM200103153441101" } }, { "attribution_basis": "SOURCE_CITED", "credit": "historical_scientific", "entity_kind": "historical_person", "name": "Alex Bajamonde", "note": "Archive attribution; detailed role assignment remains source-bound", "roles": [ "discoverer" ], "source": { "citation": "Slamon et al., trastuzumab plus chemotherapy for HER2-positive metastatic breast cancer", "url": "https://www.nejm.org/doi/full/10.1056/NEJM200103153441101" } }, { "attribution_basis": "SOURCE_CITED", "credit": "historical_scientific", "entity_kind": "historical_person", "name": "Thomas Fleming", "note": "Archive attribution; detailed role assignment remains source-bound", "roles": [ "discoverer" ], "source": { "citation": "Slamon et al., trastuzumab plus chemotherapy for HER2-positive metastatic breast cancer", "url": "https://www.nejm.org/doi/full/10.1056/NEJM200103153441101" } }, { "attribution_basis": "SOURCE_CITED", "credit": "historical_scientific", "entity_kind": "historical_person", "name": "Wolfgang Eiermann", "note": "Archive attribution; detailed role assignment remains source-bound", "roles": [ "discoverer" ], "source": { "citation": "Slamon et al., trastuzumab plus chemotherapy for HER2-positive metastatic breast cancer", "url": "https://www.nejm.org/doi/full/10.1056/NEJM200103153441101" } }, { "attribution_basis": "SOURCE_CITED", "credit": "historical_scientific", "entity_kind": "historical_person", "name": "Janet Wolter", "note": "Archive attribution; detailed role assignment remains source-bound", "roles": [ "discoverer" ], "source": { "citation": "Slamon et al., trastuzumab plus chemotherapy for HER2-positive metastatic breast cancer", "url": "https://www.nejm.org/doi/full/10.1056/NEJM200103153441101" } }, { "attribution_basis": "SOURCE_CITED", "credit": "historical_scientific", "entity_kind": "historical_person", "name": "Mark Pegram", "note": "Archive attribution; detailed role assignment remains source-bound", "roles": [ "discoverer" ], "source": { "citation": "Slamon et al., trastuzumab plus chemotherapy for HER2-positive metastatic breast cancer", "url": "https://www.nejm.org/doi/full/10.1056/NEJM200103153441101" } }, { "attribution_basis": "SOURCE_CITED", "credit": "historical_scientific", "entity_kind": "historical_person", "name": "Jose Baselga", "note": "Archive attribution; detailed role assignment remains source-bound", "roles": [ "discoverer" ], "source": { "citation": "Slamon et al., trastuzumab plus chemotherapy for HER2-positive metastatic breast cancer", "url": "https://www.nejm.org/doi/full/10.1056/NEJM200103153441101" } }, { "attribution_basis": "SOURCE_CITED", "credit": "historical_scientific", "entity_kind": "historical_person", "name": "Larry Norton", "note": "Archive attribution; detailed role assignment remains source-bound", "roles": [ "discoverer" ], "source": { "citation": "Slamon et al., trastuzumab plus chemotherapy for HER2-positive metastatic breast cancer", "url": "https://www.nejm.org/doi/full/10.1056/NEJM200103153441101" } } ], "evidence": [ { "description": "Bibliographic/stated-result source; not a WRS proof verification", "id": "source-0", "kind": "source_reference", "source": { "citation": "Slamon et al., trastuzumab plus chemotherapy for HER2-positive metastatic breast cancer", "url": "https://www.nejm.org/doi/full/10.1056/NEJM200103153441101" } }, { "description": "Bibliographic/stated-result source; not a WRS proof verification", "id": "source-1", "kind": "source_reference", "source": { "citation": "Crossref record for trastuzumab metastatic-breast-cancer trial", "url": "https://api.crossref.org/works/10.1056%2FNEJM200103153441101" } } ], "origin": "HUMAN_LEGACY", "record_profile": "wrs-local-research-notes-0.1", "record_type": "research_note", "rrp_version": "0.1", "scope": { "description": "The record is the exact 2001 NEJM trial and its enrolled population, regimens and follow-up. HER2 biology, antibody engineering, adjuvant trials, later regimens and population-wide impact remain separate.", "domain": "Oncology" }, "sources": [ { "citation": "Slamon et al., trastuzumab plus chemotherapy for HER2-positive metastatic breast cancer", "url": "https://www.nejm.org/doi/full/10.1056/NEJM200103153441101" }, { "citation": "Crossref record for trastuzumab metastatic-breast-cancer trial", "url": "https://api.crossref.org/works/10.1056%2FNEJM200103153441101" } ], "statement": "# Slamon and colleagues: trastuzumab plus chemotherapy in HER2-positive metastatic breast cancer\n\nReported a randomized clinical comparison in HER2-overexpressing metastatic breast cancer in which adding trastuzumab to first-line chemotherapy improved measured clinical outcomes while identifying important cardiotoxicity.\n\n## Scientific scope\n\nThe record is the exact 2001 NEJM trial and its enrolled population, regimens and follow-up. HER2 biology, antibody engineering, adjuvant trials, later regimens and population-wide impact remain separate.\n\n## Reading status\n\nThis is a source-linked WRS catalogue note. A full explanatory guide and independent scientific reconstruction have not been completed for this entry. Read the identified original work for its complete narrative and arguments.\n\n## People and systems\n\nDennis J. Slamon; Brian Leyland-Jones; Steven Shak; Hank Fuchs; Virginia Paton; Alex Bajamonde; Thomas Fleming; Wolfgang Eiermann; Janet Wolter; Mark Pegram; Jose Baselga; Larry Norton\n\nThe named authors contributed to this scoped work; individual effort shares and later applications are not assigned by the byline.\n\n\n\n## Original sources\n\n- [Slamon et al., trastuzumab plus chemotherapy for HER2-positive metastatic breast cancer](https://www.nejm.org/doi/full/10.1056/NEJM200103153441101)\n- [Crossref record for trastuzumab metastatic-breast-cancer trial](https://api.crossref.org/works/10.1056%2FNEJM200103153441101)\n", "summary": "Reported a randomized clinical comparison in HER2-overexpressing metastatic breast cancer in which adding trastuzumab to first-line chemotherapy improved measured clinical outcomes while identifying important cardiotoxicity.", "title": "Slamon and colleagues: trastuzumab plus chemotherapy in HER2-positive metastatic breast cancer" }, "record_id": "urn:uuid:a95a86e3-8343-486e-a365-ba2437a1e761", "version": 1, "source_ref": { "record_id": "urn:uuid:a95a86e3-8343-486e-a365-ba2437a1e761", "version": 1, "content_hash": "sha256:b3839bd4ccbbd893da879c608d3775c1b818109b6a849a9db63af7f5967d9ad5" }, "export_view": "wrs-public-editorial-view-1", "public_view_hash": "sha256:d73156554a5244d8883bbc446394ec716c4e0ffadcfefbdd9ead9e514262c220" }, "target": { "record_id": "urn:uuid:a95a86e3-8343-486e-a365-ba2437a1e761", "version": 1, "content_hash": "sha256:b3839bd4ccbbd893da879c608d3775c1b818109b6a849a9db63af7f5967d9ad5" }, "published_grade": { "profile": "wrs-published-grade-1", "edition": "2026-10-28.1", "id": "slamon-trastuzumab-metastatic-breast-cancer-2001", "entry_id": "slamon-trastuzumab-metastatic-breast-cancer-2001", "revision": 1, "title": "Slamon and colleagues: trastuzumab plus chemotherapy in HER2-positive metastatic breast cancer", "context": "Clinical oncology", "track": "Randomized clinical evidence", "band": "A", "modifier": "+", "status": "PROVISIONAL_EDITORIAL", "assessed_on": "2026-09-25", "evidence_cutoff": "2026-09-25", "achievement_state": "SUPPORTED_SCOPED_RESULT", "what_changed": "HER2-targeted antibody benefit was demonstrated in a defined metastatic treatment setting.", "scope": "Exact 12-author 2001 trial, its patients/regimens/follow-up; adjuvant trials and later therapy separate.", "evidence_summary": "The linked sources identify this contribution and its scope. WRS has not independently reconstructed the scientific claims. The record is the exact 2001 NEJM trial and its enrolled population, regimens and follow-up. HER2 biology, antibody engineering, adjuvant trials, later regimens and population-wide impact remain separate.", "references": [ { "title": "Slamon et al., trastuzumab plus chemotherapy for HER2-positive metastatic breast cancer", "url": "https://www.nejm.org/doi/full/10.1056/NEJM200103153441101", "locator": "Source for the stated contribution; scientific claims remain bounded to the linked work." }, { "title": "Crossref record for trastuzumab metastatic-breast-cancer trial", "url": "https://api.crossref.org/works/10.1056%2FNEJM200103153441101", "locator": "Source for the stated contribution; scientific claims remain bounded to the linked work." } ], "roles": [ { "who": "The named authors listed in the linked research record", "credit": "SCIENCE", "did": "Complete source byline retained in the research record; this collective display does not merge person identities or measure labor shares." } ], "target": { "record_id": "urn:uuid:a95a86e3-8343-486e-a365-ba2437a1e761", "version": 1, "content_hash": "sha256:b3839bd4ccbbd893da879c608d3775c1b818109b6a849a9db63af7f5967d9ad5" }, "scientific_correctness_certified": false, "independent_expert_calibration": false, "method": "PROPRIETARY", "points": "245000" }, "canonical_agent_submission": false, "scientific_verification_awarded": false, "reader_guide": null, "reading_status": "SOURCE_LINKED_NOTE" }